Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a session on emerging treatment strategies for bone marrow failure (BMF) syndromes including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs) and aplastic anemia (AA). This session highlighted the growing number of novel agents and ongoing clinical trials for these conditions despite the COVID-19 pandemic. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.